Wednesday, July 03, 2024
Owkin, a prominent AI-biotech firm, has expanded into the DACH region (Germany, Austria, and Switzerland) by forming partnerships with nine leading institutions. These include Charité – Universitätsmedizin Berlin, Centre Hospitalier Universitaire Vaudois (CHUV), Universitätsspital Basel, Technical University of Munich (TUM), Uniklinikum Erlangen, Universitätsklinikum Leipzig, Inselspital Bern, Universitätsklinik Mannheim-Heidelberg, and Medical University of Vienna. These collaborations cover a substantial portion of the region's patient population, enhancing Owkin's access to diverse healthcare data for precision medicine applications.
Guillaume Bézie, Director of Partnerships for Western Europe, underscored the strategic importance of these collaborations for Owkin's expansion. By leveraging extensive patient datasets from these institutions, Owkin aims to advance AI-driven drug discovery and diagnostics in key fields such as Prostate Cancer, Muscle Invasive Bladder Cancer (MIBC), and Cardiovascular Disease (CVD). The initiatives focus on discovering biomarkers, predicting treatment responses, and developing personalized therapies.
Specific projects include BiomarkerPlus for predicting outcomes in early-stage prostate cancer, TargetMatch for identifying treatment targets in MIBC, TrialPlus for optimizing clinical trials in CVD, and enhancing AI diagnostics with their MSIntuit® CRC tool. These efforts aim to accelerate research and enhance patient care through advanced data analytics and machine learning.
Dr. Philipp Mann, Principal Partnerships Manager for the DACH region, emphasized the transformative potential of Owkin's collaborations. By harnessing comprehensive health data, these partnerships seek to drive innovation in healthcare, ultimately leading to improved medical outcomes and personalized treatment strategies across various medical disciplines.
Source: businesswire.com
